Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2020 16:05 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference

ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
November 27, 2019 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Present at Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
November 20, 2019 21:18 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...
November 19, 2019 16:14 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...
November 19, 2019 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

-Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell...
October 28, 2019 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results

-Provides update from ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies- -Began treating patients in Phase 1/2 clinical trial of CTX110™, targeting...
October 15, 2019 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

- CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs - - KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous...
October 01, 2019 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Present at Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
September 17, 2019 07:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019

-New data demonstrate successful differentiation of CRISPR-edited human pluripotent stem cells to pancreatic precursor cells- ZUG, Switzerland, CAMBRIDGE, Mass., and SAN DIEGO, Sept. 17, 2019 ...
July 31, 2019 07:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Present at Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...